News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioCardia and Juventas Therapeutics, Inc. Announce Phase II Development Program of JVS-100 Delivered With the Helical Infusion System to Treat Heart Failure


3/15/2012 6:20:34 AM

SAN CARLOS, Calif.--(BUSINESS WIRE)--BioCardia, a leading provider of cardiovascular catheter systems designed to deliver biologic therapies for cardiac regeneration and Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announced today that they will continue to work together to execute Juventas’ Phase II trial of JVS-100 for the treatment of heart failure.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES